会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • REDUCED-MASS, LONG-ACTING DOSAGE FORMS
    • 减少质量,长效剂型
    • WO2008153997A1
    • 2008-12-18
    • PCT/US2008/007216
    • 2008-06-09
    • BROOKWOOD PHARMACEUTICALS, INC.TICE, Thomas, R.MARKLAND, PeterSTAAS, Jay, K.
    • TICE, Thomas, R.MARKLAND, PeterSTAAS, Jay, K.
    • A01N43/04A61K31/70A61K39/395
    • C07K16/00A61K9/0048A61K9/0051A61K9/1647A61K31/7088A61K2039/505
    • Methods and compositions are disclosed whereby free antibody or nucleic acid coadministered with a long-acting formulation, such as microparticle or implant, containing the antibody or nucleic acid to achieve a long duration of antibody or nucleic acid release In one aspect, the free antibody or nucleic acid alone has efficacy for an extended period, during which time, very little or no long-acting formulation antibody or nucleic acid is released In one aspect, after the free antibody or nucleic acid has diminished activity, Is gone, or no longer has activity, the longacting formulation antibody or nucleic acid begins to release for a desired preprogrammed duration to provide long-acting durations Less formulation mass is needed because the entire antibody or nucleic acid Is not encapsulated or implanted with encapsulation or implant excipient or polymer In addition, more antibody or nucleic acid can be administered to afford longer-acting formulations.
    • 公开了方法和组合物,其中与长效制剂(例如微粒或植入物)共同施用含有抗体或核酸以实现长时间抗体或核酸释放的游离抗体或核酸。一方面,游离抗体或 单独的核酸具有长时间的功效,在此期间,非常少的或没有长效的制剂抗体或核酸被释放。一方面,在游离抗体或核酸活性降低之后,已经去除或不再具有 活性,长效制剂抗体或核酸开始释放所需的预编程持续时间以提供长效持续时间需要较少的制剂质量,因为整个抗体或核酸不被包封或植入用包封或植入物赋形剂或聚合物。此外, 可以施用更多的抗体或核酸以提供长效制剂。